Abstract |
Perinatal hypoxic ischemia (H-I) causes brain damage and long-term neurological impairments, leading to motor dysfunctions and cerebral palsy. Many studies have demonstrated that the TrkB-ERK1/2 signaling pathway plays a key role in mediating the protective effect of brain-derived neurotrophic factor ( BDNF) following perinatal H-I brain injury in experimental animals. In the present study, we explored the neuroprotective effects of the TrkB-specific agonist monoclonal antibody 29D7 on H-I brain injury in neonatal rats. First, we found that intracerebroventricular (icv) administration of 29D7 in normal P7 rats markedly increased the levels of phosphorylated ERK1/2 and phosphorylated AKT in neurons up to 24 h. Second, P7 rats received icv administration of 29D7 and subjected to H-I injury induced by unilateral carotid artery ligation and exposure to hypoxia (8% oxygen). We found that 29D7, to a similar extent to BDNF, significantly inhibited activation of caspase-3, a biochemical hallmark of apoptosis, following H-I injury. Third, we found that this 29D7-mediated neuroprotective action persisted at least up to 5 weeks post-H-I injury as assessed by brain tissue loss, implicating long-term neurotrophic effects rather than an acute delay of cell death. Moreover, the long-term neuroprotective effect of 29D7 was tightly correlated with sensorimotor functional recovery as assessed by a tape-removal test, while 29D7 did not significantly improve rotarod performance. Taken together, these findings demonstrate that pretreatment with the TrkB-selective agonist 29D7 significantly increases neuronal survival and behavioral recovery following neonatal hypoxic-ischemic brain injury.
|
Authors | Gab Seok Kim, Seongeun Cho, James W Nelson, Gregory J Zipfel, Byung Hee Han |
Journal | PloS one
(PLoS One)
Vol. 9
Issue 2
Pg. e88962
( 2014)
ISSN: 1932-6203 [Electronic] United States |
PMID | 24551199
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies
- Neuroprotective Agents
- Receptor, trkB
- Proto-Oncogene Proteins c-akt
- Extracellular Signal-Regulated MAP Kinases
- Caspase 3
|
Topics |
- Animals
- Animals, Newborn
- Antibodies
(administration & dosage, pharmacology)
- Body Temperature
(drug effects)
- Caspase 3
(metabolism)
- Cell Survival
(drug effects)
- Enzyme Activation
(drug effects)
- Extracellular Signal-Regulated MAP Kinases
(metabolism)
- Female
- Hypoxia-Ischemia, Brain
(drug therapy, enzymology, pathology, physiopathology)
- Injections, Intraventricular
- Male
- Motor Activity
(drug effects)
- Neuroprotective Agents
(pharmacology, therapeutic use)
- Phosphorylation
(drug effects)
- Proto-Oncogene Proteins c-akt
(metabolism)
- Rats
- Rats, Sprague-Dawley
- Receptor, trkB
(agonists, metabolism)
- Sensory Receptor Cells
(drug effects, enzymology, pathology)
|